Overview
rs1695 is a genetic variant on gene GSTP1 associated with Spondyloepiphyseal dysplasia.
This variant is located on chromosome 11. The variations at position 67585218 are the genetic letters A/A, G/G, T/T, G/T, A/T, A/G
Since humans have each twice (one from each parent), these letter-variations occur on both chromosomes. People can have the same or different letters on both chromosomes. Every person's individual variation combination is referred to as genotype. For variant rs1695 there are 6 currently known genotypes : A/A, G/G, T/T, G/T, A/T or A/G
Short Overview
Variant Location
rs1695 is located on gene GSTP1 in chromsome 11. Use the genome browser to explore the location of rs1695 and its genetic neighbourhood.
Pharmacogenetics
rs1695 affects the following drugs:
Genome Browser
This interactive browser visualizes what no human can see with the naked eye - our DNA. From a down to a specific position on a . The position you are looking at here is the exact location of variant rs on gene GSTP1. Explore more variants and their effects on the body by browsing left and right along the DNA strand.
Did you know genetic variants affect drugs?
Mutations are changes in genes and genetic variations are differences in the DNA among people. Variants are tiny changes in just one piece of the DNA while haplotypes are groups of these changes that usually come together.
Conditions & Traits of rs1695
The different genotypes of variant rs1695 can affect the likelyhood of developing certain traits or conditions. Current research shows that 1 condition and 0 traits are associated with rs1695. The following table shows the relationship between genotypes and conditions and traits.
Classification of Variants
Variants can be classified either based on scientific studies or clinical tests. Scientific studies classifications aim to uncover the function of genetic variants and their role in conditions, traits, and evolution. Variants are categorized according to their functional effect, such as loss-of-function (reduced gene activity), gain-of-function (increased gene activity), neutral (no significant impact) or evolutionary conservation. This classification uses experimental data, population studies, and computational analyses to understand the long-term effects of variants. Clinical testing classifications, however, focus on the immediate health impact on the human body, distinguishing five categories from disease causing (harmful) to no effect (not harmful). This classification relies on a mix of family history, lab tests, and computer predictions, aiming to assist doctors in making medical decisions.
Condition
1Genotype
A
A
Level of evidence
Sources
No effect
Unisex
2 Sources
Participants: 0
The genotype with the letters A/A is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Genotype
G
G
Level of evidence
Sources
No effect
Unisex
2 Sources
Participants: 0
The genotype with the letters G/G is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Genotype
A
G
Level of evidence
Sources
No effect
Unisex
2 Sources
Participants: 0
The genotype with the letters A/G is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Pharmacogenetics
The genetic variant rs1695 impacts how certain medications work in the body. This difference may cause some of us to require different dosage amounts to achieve the desired effects, while others might experience more apparent side-effects. As a result, healthcare providers may need to adjust prescriptions for those individuals with rs1695. Ultimately, understanding our genetic makeup helps improve the overall effectiveness and usability of medications. Tailoring treatments based on genetics ensures a safer, more personalized healthcare experience.
Genotype
Level of evidence
Impacts
Summary
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/A have decreased Drug Effect to CAPECITABINE.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/G have decreased Drug Effect to CAPECITABINE.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype G/G have increased Drug Effect to CAPECITABINE.
more info
Legend:
Increased
Decreased
No known effect
Genotype
Level of evidence
Impacts
Summary
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/A have increased Drug Effect and increased Side Effects to CISPLATIN.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/G have decreased Drug Effect and increased Side Effects to CISPLATIN.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype G/G have decreased Drug Effect and increased Side Effects to CISPLATIN.
more info
Legend:
Increased
Decreased
No known effect
Genotype
Level of evidence
Impacts
Summary
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/A have increased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/G have increased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype G/G have decreased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.
more info
Legend:
Increased
Decreased
No known effect
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype A/A have decreased Drug Effect to CAPECITABINE.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype A/G have decreased Drug Effect to CAPECITABINE.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype G/G have increased Drug Effect to CAPECITABINE.
Level of evidence
More info
Legend:
Increased
Decreased
No known effect
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype A/A have increased Drug Effect and increased Side Effects to CISPLATIN.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype A/G have decreased Drug Effect and increased Side Effects to CISPLATIN.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype G/G have decreased Drug Effect and increased Side Effects to CISPLATIN.
Level of evidence
More info
Legend:
Increased
Decreased
No known effect
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype A/A have increased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype A/G have increased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype G/G have decreased Drug Effect and increased Side Effects to CYCLOPHOSPHAMIDE.
Level of evidence
More info
Legend:
Increased
Decreased
No known effect
Drugs related to rs1695
All drugs that are linked to rs1695 are listed here.
Studies and Sources
All of the resources below examine variant rs1695
Yi Zhu, Jian-Hua Yang, Jun-Ping Hu, Ming Qiao
Paula Muñiz, Cristina Andrés-Zayas, Diego Carbonell, María Chicano, Rebeca Bailén, Gillen Oarbeascoa, Julia Suárez-González, Ignacio Gómez Centurión, Nieves Dorado, David Gallardo, Javier Anguita, Mi Kwon, Jose L. Díez-Martín, Carolina Martínez-Laperche, Ismael Buño
Yuan Liu, Rui Wang, Peizhen Wen, Wenbin An, Jinxin Zheng, Tao Zhang, Pengshan Zhang, Haoyu Wang, Fan Zou, Hui Pan, Junwei Fan, Zhihai Peng